Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies

International Journal of Urology

Volumn 21, Issue 8, 2014, Pages 786-792

  Leal, Jose ^a   Hamdy, Freddie ^a   Wolstenholme, Jane ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cost effectiveness; Ethnicity; Meta regression; Prevalence; Prostate cancer; Prostate specific antigen screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; AUTOPSY; CANCER SCREENING; CAUCASIAN; CHINESE; ETHNIC DIFFERENCE; ETHNIC GROUP; ETHNICITY; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; VERY ELDERLY; AGE; ASYMPTOMATIC DISEASES; BAYES THEOREM; ETHNOLOGY; MASS SCREENING; META ANALYSIS; PATHOLOGY; PROSTATE; PROSTATE TUMOR; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASYMPTOMATIC DISEASES; BAYES THEOREM; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PROSTATE; PROSTATIC NEOPLASMS; YOUNG ADULT;

EID: 84905051858     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12458     Document Type: Article

References (35)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 2001; 37: 4-66.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007; 18: 581-592.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
4. Hussain S, Gunnell D, Donovan J etal. Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int. 2008; 101: 547-555.
5. Ciatto S, Gervasi G, Bonardi R etal. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). Eur. J. Cancer 2005; 41: 411-415.
6. Draisma G, Boer R, Otto SJ etal. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J. Natl. Cancer Inst. 2003; 95: 868-878.
7. Etzioni R, Penson DF, Legler J etal. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J. Natl. Cancer Inst. 2002; 94: 981-990.
8. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2012; 157: 120-134.
9. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer. Part II: estimating the risks, benefits, and costs. American College of Physicians. Ann. Intern. Med. 1997; 126: 468-479.
10. Cowen ME, Chartrand M, Weitzel WF. A Markov model of the natural history of prostate cancer. J. Clin. Epidemiol. 1994; 47: 3-21.
11. Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptomatic incidence and duration of prostate cancer. Am. J. Epidemiol. 1998; 148: 775-785.
12. Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med. Decis. Making. 2008; 28: 323-331.
13. Thompson IM, Optenberg SA. An overview cost-utility analysis of prostate cancer screening. Oncology (Williston Park) 1995; 9: 141-145.
14. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J. Urol. 1990; 143: 742-746.
15. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: prior probability and effectiveness of tests. The American College of Physicians. Ann. Intern. Med. 1997; 126: 394-406.
16. Claxton K, Sculpher M, McCabe C etal. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005; 14: 339-347.
17. Baron E, Angrist A. Incidence of occult adenocarcinoma of the prostate after 50 years of age. Arch. Pathol. 1941; 32: 787-793.
18. Bean MA, Yatani R, Liu PI, Fukazawa K, Ashley FW, Fujita S. Prostatic carcinoma at autopsy in Hiroshima and Nagaski Japanese. Cancer 1973; 32: 498-506.
19. Gaynor EP. Zur Frage des Prostatakrebses. Virchows Arch. Pathol. Anat. Physiol. Klin. Med. 1938; 301: 602-652.
20. Franks LM. Latent carcinoma of the prostate. J. Pathol. Bacteriol. 1954; 68: 603-616.
21. Akpolat N, Buyuk Y, Uzun I, Gecit I, Kurnaz G. Prevalence of latent prostate cancer and prostatic intraepithelial neoplais in Istanbul, Turkey: an autopsy study. Turk. J. Med. Sci. 2012; 42: 449-456.
22. Zare-Mirzaie A, Balvayeh P, Imamhadi MA, Lofti M. The frequency of latent prostate carcinoma in autopsies of over 50 years old males, the Iranian experience. Med. J. Islam. Repub. Iran 2012; 26: 73-77.
23. Zlotta AR, Egawa S, Pushkar D etal. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J. Natl. Cancer Inst. 2013; 105: 1050-1058.
24. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat. Med. 2002; 21: 1559-1573.
25. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat. Comput. 2000; 10: 325-337.
26. Cowles MK, Carlin BP. Markov Chain Monte Carlo convergence diagnostics: a comparative review. J. Am. Stat. Assoc. 1996; 91: 883-904.
27. Spiegelhalter DJ, Best NG, Carlin BP, Van der Linde A. Bayesian measures of model complexity and fit (with Discussion). J. R. Stat. Soc. Series B Stat. Methodol. 2002; 64: 583-616.
28. Schmalhorst WR, Halpert B. Carcinoma of the prostate gland in patients more than 80 years old. Am. J. Clin. Pathol. 1964; 42: 170-173.
29. Halpert B, Schmalhorst WR. Carcinoma of the prostate in patients 70 to 79 years old. Cancer 1966; 19: 695-698.
30. Lundberg S, Berge T. Prostatic carcinoma. An autopsy study. Scand. J. Urol. Nephrol. 1970; 4: 93-97.
31. Schroder FH, Hugosson J, Roobol MJ etal. Prostate-cancer mortality at 11 years of follow-up. N. Engl. J. Med. 2012; 366: 981-990.
32. Andriole GL, Crawford ED, Grubb RL etal. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J. Natl. Cancer Inst. 2012; 104: 125-132.
33. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in Black than in White American men, and influences racial progression and mortality disparity. J. Urol. 2010; 183: 1792-1796.
34. Jack RH, Davies EA, Moller H. Testis and prostate cancer incidence in ethnic groups in South East England. Int. J. Androl. 2007; 30: 215-221.
35. Konety BR, Bird VY, Deorah S, Dahmoush L. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J. Urol. 2005; 174: 1785-1788.